The administration of reserpine to rodents was one of the first models used to investigate the
pathophysiology and screening for potential treatments of P arkinson's disease (PD). The …

Complex interactions between genes and environment result in a sodium-induced elevation
in blood pressure (salt sensitivity) and/or hypertension that lead to significant morbidity and …

Animal models are widely used to study alterations caused by Parkinson's disease (PD).
However, in general, pharmacological models do not express the progressive nature of the …

Tardive dyskinesia (TD) is a motor disorder of the orofacial region resulting from chronic
neuroleptic treatment. A high incidence and irreversibility of this hyperkinetic disorder has …

Studies have suggested that cognitive deficits can precede motor alterations in Parkinson's
disease (PD). However, in general, classic animal models are based on severe motor …

Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents
antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's …

Progressive neurodegenerative disorders such as Parkinson Disease (PD) lack curative or
long-term treatments. At the same time, the increase of the worldwide elderly population …

Monosialoganglioside (GM1) is a glycosphingolipid that protects against some neurological
conditions, such as seizures and ischemia. Glutaric acidemia type I (GA-I) is an inherited …

For more than 50 years, Parkinson's disease (PD) has been conceptualized as a product of
nigro-striatal dopamine (NSD) system degeneration. In spite of a growing body of evidence …

Rationale Reserpine, a monoamine-depleting agent, which irreversibly and non-selectively
blocks the vesicular monoamine transporter, has been used as an animal model to study …